Teva-affiliated Clonidine Transdermal System recalls 113,943 cartons after CGMP deviations. Unapproved raw material prompts recall. Stop use immediately and contact Teva or a healthcare provider for guidance.
CGMP Deviations: use of an unapproved raw material
Consumers and healthcare providers should stop using this product immediately. Contact Teva Pharmaceuticals USA, Inc or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Clonidine transdermal system delivers clonidine through the skin to treat high blood pressure and certain other conditions.
CGMP deviations indicate an unapproved raw material was used in production, which could affect drug quality and safety.
This recall is not described as part of a broader industry pattern in the provided data.
No targeted injuries reported in the notice; however, the recall emphasizes quality control risk and potential unsafe drug product.
NDC numbers printed on carton and pouch; lot numbers on carton seals and foil packaging
No remediation timeframe provided in the notice; expect recall communications by Teva and FDA updates
Keep recall notice, lot numbers, expiration dates, and any correspondence with manufacturer.
Brand: CLONIDINE TRANSDERMAL SYSTEM. Manufacturer: Actavis Laboratories UT Inc., Salt Lake City, UT 84108. Distributor: Teva Pharmaceuticals USA, Inc. NDC 0591-3510-04 carton, 0591-3510-54 pouch. Quantity: 113,943 cartons. Form: 0.3 mg/day transdermal system. Pack: cartons of 4 Systems and 4 Adhesive Covers. Route: Rx only. Distribution: Within the U.S. Models/lot information in play: Lot 100053892 (Exp. 04/2026), Lot 100057899 (Exp. 05/2026), Lot 100062704 (Exp. 02/2027). Dates: Recall date 2026-03-19. Status: ACTIVE.
No specific injuries or incidents are described in the provided recall notice.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Teva Pharmaceuticals recalled 124,054 cartons of Clonidine Transdermal System due to CGMP deviations from an unapproved raw material. The recall affects products sold in the United States. Consumers should stop using the product immediately and consult a healthcare provider for guidance.
Teva Pharmaceuticals recalled 67,043 bottles of Metoprolol Succinate Extended-Release Tablets, 50 mg, distributed nationwide. The FDA enforcement report cites Failed Dissolution Specifications as the hazard. Health care providers and patients should stop using this product immediately and contact Teva for guidance.
Teva Pharmaceuticals USA, Inc. recalls 8,376 isotretinoin 40 mg capsules distributed to FL, OH, PR and MS after FDA enforcement report flags superpotent and subpotent lots. Patients should stop use and contact their healthcare providers for guidance.
Teva Pharmaceuticals USA, Inc. recalls 21,984 packages of Isotretinoin Capsules, USP, 30 mg. The lots are distributed to Florida, Ohio, Puerto Rico and Mississippi. The recall is active as of April 15, 2026.
Actavis Laboratories recalled 15,944 cartons of Testosterone Gel on November 7, 2025. The recall follows a defect in the side-seal of the containers, which may allow product leakage. Consumers must stop using the product immediately and contact their healthcare providers for guidance.